U.S. President Donald Trump \said his administration will be suing some drug companies as part of its fight against the opioid drug crisis, without giving more detail.
The American Health Policy Institute (AHPI) released “’Tipping Points’ of Employer-Sponsored Health Insurance,” which examines various factors that could impact broad-based employer-provided health coverage.
GlaxoSmithKline will not make a play for Pfizer’s consumer health business. The British pharma giant’s decision came one day after another potential buyer, Reckitt Benckiser Group, announced that it would not seek to buy the Pfizer business unit, which is valued between $15 and $20 billion.
A panel of European Medicines Agency recommended against granting marketing approval to Portola Pharmaceuticals Inc.’s oral blood thinner, saying the benefits of the drug did not outweigh risks.
Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.
A panel of European Medicines Agency recommended approval for GlaxoSmithKline’s two-drug regimen to treat HIV, the virus that causes AIDS.
Shares in Britain’s Indivior were hammered on Friday after the company lost a second legal case in recent months in an attempt to protect the patent of an opioid addiction treatment that generates 80 percent of its revenues.
How do you view organizational politics? What do we really mean when we talk about being politically savvy? And what is the link between gender, political skill and effective leadership? Join this webinar for a fresh look at knowledge, skills and behaviors that contribute to political adeptness and better understand the role these competencies play in realizing your leadership potential.
Amicus Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare approved the oral small molecule pharmacological chaperone Galafold capsules 123mg (migalastat).
LevLane has been named agency of record for Ilera Healthcare, Pennsylvania’s premier medical cultivator, processor and dispenser
GSW, a Syneos Health company, named Marc Lineveldt as Executive Creative Director. Lineveldt will lead agency-wide initiatives that drive strategic creativity for GSW Columbus’s deep roster of domestic and global healthcare clients.
Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.
Novartis announced that the U.S. Food and Drug Administration expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Shares of Array BioPharma Inc. climbed after the company released detailed results for its late-stage combination treatment for metastatic melanoma.
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals signed a collaboration deal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.
Ogilvy CommonHealth Worldwide announced the appointment of Andrew Schirmer to the role of chief executive officer, Ogilvy CommonHealth (OCH) North America.
For the 3rd year, three agencies – AbelsonTaylor, HCB Health, and Juice Pharma Worldwide – hosted an “Innovation in Healthcare” event at SXSW that featured the MIT Hacking Medicine team.
AbbVie Inc. said the drugmaker would not seek accelerated approval for the company’s experimental lung cancer treatment based on the results from a mid-stage study.
Cimzia label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.
UCB announced that the U.S. Food and Drug Administration (FDA) approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia (certolizumab pegol) through placenta and minimal transfer to breast milk from mother to infant.
Pharmaceutical marketers need to adapt to the value-centric marketplace and deliver the desired messaging and adjunctive, innovative services that align their products with the value perception the new marketplace demands.